文献速递泌尿生殖与妇科肿瘤放疗

阴道残端近距离治疗boost与II期子宫内膜样癌总生存改善相关

Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer.
PubMed 文献 · Adv Radiat Oncol · 2026-06-23

基于2023年美国国家癌症数据库的回顾性分析纳入1782例FIGO(2009)II期子宫内膜样癌患者,比较全盆腔放疗(WPRT)联合阴道残端近距离治疗(VCB)boost与单纯WPRT的生存差异。中位随访6.5年,多因素分析显示WPRT+VCB与总生存改善相关(HR 0.68,95%CI 0.55-0.83,P<.001),倾向性评分匹配后该获益维持(HR 0.61,95%CI 0.47-0.79,P<.001)。

要点

  • FIGO(2009)II期子宫内膜样癌辅助WPRT+VCB较单纯WPRT与更好OS相关。
  • 多因素分析HR 0.68(95%CI 0.55-0.83,P<.001),匹配后HR 0.61(95%CI 0.47-0.79,P<.001)。
  • 数据库回顾性分析存在局限,需在分子分型队列中进一步验证。

核心结论

  • 辅助WPRT+VCB较单纯WPRT与FIGO(2009)II期子宫内膜样癌患者总生存改善相关。

研究设计与样本

  • 回顾性查询2023年美国国家癌症数据库,纳入行子宫切除及完整手术分期、符合T2N0M0并接受辅助WPRT+VCB或单纯WPRT的子宫内膜样癌患者。
  • 排除淋巴血管间隙浸润、腹腔细胞学、肌层浸润及手术切缘等危险因素信息不完整者,共纳入1782例,其中单纯WPRT 670例、WPRT+VCB 1112例,中位随访6.5年。

主要发现

  • 逻辑回归分析显示少有 demographic 或病理特征可预测所接受的辅助治疗方案。
  • WPRT+VCB与OS获益相关,多因素分析HR 0.68(95%CI 0.55-0.83),P<.001。
  • 倾向性评分匹配后WPRT+VCB的OS获益维持,多因素分析HR 0.61(95%CI 0.47-0.79),P<.001。

关键数值与推荐

  • 现有指南推荐全盆腔放疗(WPRT),阴道残端近距离治疗(VCB)作为boost仅获条件性支持。

临床怎么用

  • 对于FIGO(2009)II期子宫内膜样癌术后患者,可考虑在WPRT基础上联合VCB boost以改善总生存。
  • 治疗决策时应结合分子分型等进一步证据,并注意数据库研究的固有局限。

局限性

  • 本研究为美国国家癌症数据库回顾性分析,存在数据库研究固有局限,作者建议在分子ly defined队列中进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment of International Federation of Gynecology and Obstetrics (FIGO, 2009) stage II endometrial cancers (ECs) typically involves total hysterectomy and bilateral salpingo-oophorectomy followed by adjuvant radiation and/or chemotherapy. Existing guidelines recommend whole pelvis radiation therapy (WPRT); however, vaginal cuff brachytherapy (VCB) has conditional support as a boost. We sought to evaluate if there is improved overall survival (OS) associated with WPRT + VCB over WPRT alone for patients with FIGO (2009) stage II endometrioid EC and assess patterns of care. We hypothesize that WPRT + VCB will be associated with improved survival. METHODS AND MATERIALS: The 2023 National Cancer Database was queried for patients with endometrioid ECs who underwent hysterectomy with complete surgical staging, consistent with T2N0M0, and were treated adjuvantly with WPRT + VCB or WPRT alone. Patients were excluded if risk factor information (eg, lymphovascular invasion, peritoneal cytology, myometrial invasion, and surgical margins) was incomplete. Logistic regression analysis was used to determine the propensity for each treatment method. Kaplan-Meier and landmark analyses for OS and univariate and multivariable (MVA) Cox proportional hazards models were used to evaluate (1) the entire cohort and (2) a propensity score-matched subgroup. RESULTS: Of 1782 patients included in this analysis, 670 received WPRT alone, and 1112 received WPRT + VCB. Median follow-up was 6.5 years. Logistic regression analysis revealed that few demographic or pathologic features were predictive of the adjuvant regimen received. WPRT + VCB was associated with an OS advantage (MVA: hazard ratio 0.68 [95% CI, 0.55-0.83]; P < .001). After propensity score matching, the OS benefit associated with WPRT + VCB was maintained (MVA: hazard ratio 0.61 [95% CI, 0.47-0.79]; P < .001). CONCLUSIONS: This National Cancer Database analysis suggests that adjuvant treatment with WPRT + VCB is associated with improved OS compared to WPRT alone in patients with FIGO 2009 stage II endometrioid EC. Given the limitations of such database analyses, further exploration in molecularly defined cohorts is warranted.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Atobiloye M, Howell J, Cruttenden J, et al. Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer. Adv Radiat Oncol. 2026. PMID: 42540336. doi:10.1016/j.adro.2026.102124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。